Human data suggest that reconstituted HDL (rHDL) infusion can induce atherosclerosis regression. Studies in mice indicated that rHDL infusion adversely affects VLDL levels, but this effect is less apparent in humans. This discrepancy may be explained by the fact that humans, in contrast to mice, express cholesteryl ester transfer protein (CETP).
ABsTrAcT
Human data suggest that reconstituted HDL (rHDL) infusion can induce atherosclerosis regression. Studies in mice indicated that rHDL infusion adversely affects VLDL levels, but this effect is less apparent in humans. This discrepancy may be explained by the fact that humans, in contrast to mice, express cholesteryl ester transfer protein (CETP).
The aim of this study was to investigate the role of CETP in the effects of rHDL on VLDL metabolism by using APOE*3-Leiden (E3L) mice, a well-established model for humanlike lipoprotein metabolism. At 1 h after injection, rHDL increased plasma VLDL-C and TG in E3L mice, but not in E3L mice cross-bred onto a human CETP background (E3L.CETP mice). This initial raise in VLDL was caused by competition between rHDL and VLDL for LPL-mediated TG hydrolysis, and was thus prevented by CETP. At 24 h after injection, rHDL caused a second increase in VLDL-C and TG in E3L mice, whereas rHDL even decreased VLDL in E3L.CETP mice. This secondary raise in VLDL was due to increased hepatic VLDL-TG production. Collectively, we conclude that CETP protects against the rHDL-induced increase in VLDL. We anticipate that studies evaluating the anti-atherosclerotic efficacy of rHDL in mice that are naturally deficient for CETP should be interpreted with caution, and that treatment of atherogenic dyslipidemia by rHDL should not be combined with agents that aggressively reduce CETP activity. 35 
CETP REVERSES THE RHDL-INDUCED INCREASE IN VLDL iNTroDUcTioN
Dyslipidemia is an important risk factor for cardiovascular disease (CVD). Current treatment mainly focuses on lowering of LDL-cholesterol (C), e.g. by statins. LDL-C lowering treatment results in a significant reduction in the morbidity and mortality of CVD, but can not prevent the majority of cardiovascular events 1, 2 . Prospective epidemiological studies have demonstrated a strong inverse correlation between HDL-C and CVD 3 , and recent studies revealed that high HDL-C levels are indeed protective against plaque progression 4 . Although the exact mechanisms by which HDL protects are unclear, HDL has been shown to have antioxidant, antithrombotic and anti-inflammatory properties, and to mediate reverse cholesterol transport (RCT) via the hepatobiliary route 5 . Therefore, new strategies to raise HDL-C are currently being developed to prevent and treat CVD.
Various therapeutic strategies are currently under development to raise HDL levels, including cholesteryl ester transfer protein (CETP) inhibition, niacin, upregulation of apoAI expression and infusion of apoAI mimetics or reconstituted HDL (rHDL) 6 .
Although still in early stage of development, infusion of (r)HDL seems to be a promising strategy for the treatment of CVD. Recent reviews have demonstrated that infusion of rHDL improves atherosclerotic plaque characteristics both in animal models and in humans [7] [8] [9] . For example, rHDL, composed of recombinant human apoAI Milano and phosphatidylcholine, rapidly mobilized tissue cholesterol and reduced the lipid and macrophage content of atherosclerotic plaques after a single injection into apoEdeficient mice 10 . Moreover, it prevented the progression of aortic atherosclerosis as well as promoted the stabilization of plaques after 6 weeks of administration 11 . Recent clinical trials assessed the effect of rHDL consisting of human apoAI and phosphatidylcholine (CSL-111) as a potential HDL-raising therapeutic strategy. Shortterm infusion of CSL-111 significantly improved the plaque characterization index and coronary score on quantitative coronary angiography 12 . In addition, a single dose of rHDL led to acute changes in plaque characteristics with a reduction in lipid content, macrophage size and inflammatory mediators 13 .
Albeit that rHDL thus seems to beneficially modulate atherosclerosis in mice and humans, differences have been observed with respect to modulation of VLDL levels.
Infusion of rHDL into apoE-deficient mice increased (V)LDL-C in both acute and chronic studies 10, 11 , whereas rHDL did not adversely affect (V)LDL-C in clinical studies 12, 13 .
This discrepancy may be explained by the fact that, in contrast to mice 
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. In short, In vitro LPL activity assay
The effect of rHDL on LPL activity was determined essentially as described 20 . First, glycerol tri[ At 120 min, the animals were sacrificed and blood was collected by orbital puncture for isolation of VLDL by density gradient ultracentrifugation. 35 S-apoB was measured in the VLDL fraction and VLDL-apoB production rate was shown as dpm.h -1 22 .
Statistical analysis
All data are presented as means ± SD. Data were analyzed using the unpaired Student's t test. P-values less than 0.05 were considered statistically significant. 39 
CETP REVERSES THE RHDL-INDUCED INCREASE IN VLDL resULTs
Infusion of rHDL transiently increases plasma apoAI and phospholipid levels in both E3L and E3L.CETP mice To investigate the role of CETP in the effects of rHDL infusion on VLDL metabolism, female E3L mice with or without human CETP expression received a single intravenous injection of rHDL. To assess the kinetics of rHDL that consists of humans apoAI and PL, plasma levels of human apoAI and phospholipid was determined over time ( Fig. 1) rHDL caused a transient increase in plasma human apoAI and PL levels in both E3L mice (Fig. 1A, C) and E3L.CETP mice (Fig. 1B, D) . Human apoAI and PL were cleared at a similar rate, and were disappeared from plasma after approximately 24 h. At 1 h after injection, lipoproteins in plasma were separated and the distribution of human apoAI and PL were determined (Fig. 2) . rHDL appeared to integrate into the endogenous HDL pool in both E3L and E3L.CETP mice, since both human apoAI ( Fig. 2A, B) and PL (Fig. 2C, D) eluted in fractions representing HDL. In addition, PL derived from rHDL selectively integrated into (V)LDL fraction (Fig. 2C, D) . The presence of rHDL-PL in (V)LDL is not due the presence of large rHDL aggregates that would elute in the void volume, since apoAI is not detected in the void volume (Fig. 3A) , but is explained by a time-dependent transfer of PL to endogenous VLDL as evident from incubation of rHDL with plasma from E3L mice (Fig. 3B ) and E3L.CETP mice (Fig. 3C ) in vitro. Infusion of rHDL affects plasma levels of endogenous lipids differentially in E3L and E3L.CETP mice Albeit rHDL was cleared at a similar rate in E3L and E3L.CETP mice, its effects on endogenous plasma levels of cholesterol and TG were clearly different in both mouse types (Fig. 4) . At 1 h after injection, rHDL significantly increased plasma cholesterol (C) in both E3L mice (+63%; P<0.001) (Fig. 4A) and E3L.CETP mice (+28%; P<0.01) (Fig. 4B) .
However, at 24 h after injection, rHDL still significantly increased plasma cholesterol in E3L mice (+26%, P<0.01) (Fig. 4A) but actually decreased plasma cholesterol in E3L.CETP mice (-22%, P<0.01) (Fig. 4B) . In addition, whereas rHDL caused a significant increase in plasma TG levels in E3L mice at both 1 h (+89%; P<0.01) and 24 h after injection (+67%; P<0.01) (Fig. 4C) , rHDL did not significantly increase plasma TG at any time point in E3L.
CETP mice (Fig. 4D) . At short term, rHDL raises HDL-C in E3L and E3L.CETP mice, and increases VLDL mainly in E3L mice To investigate the mechanism underlying the early effects of rHDL infusion on plasma lipids, plasma was obtained at 1 h after injection and lipoproteins were fractionated by FPLC (Fig. 5) . rHDL increased HDL-C in both E3L mice (Fig. 5A ) and E3L.CETP mice (Fig. 5B), indicating that rHDL induces a rapid cholesterol efflux from peripheral tissues into plasma. In addition, rHDL markedly increased VLDL-C (Fig. 5A ) and VLDL-TG (Fig. 5C ) in E3L mice, while its VLDL-increasing effect was only modest in E3L.CETP mice (Fig. 5B, D (Fig. 6A, C) and E3L.CETP mice (Fig. 6B, D ).
An in vitro LPL activity assay confirmed that rHDL dose-dependently decreases LPLmediated lipolysis of VLDL-like emulsion particles (Fig. 7) , whereas sucrose and sodium cholate at amounts present at the various rHDL concentrations did not (not shown).
These data thus indicate that rHDL competes for the binding of VLDL-like emulsion particles with LPL in both E3L and E3L.CETP mice, resulting in delayed clearance of TG-derived fatty acids (i.e. H-activity) as well as the resulting core remnants (i.e. 14 C-activity). The fact that rHDL does not substantially raise VLDL levels in E3L.CETP mice is thus probably related to rapid remodeling of VLDL by CETP. At long term, rHDL raises VLDL in E3L mice and decreases VLDL in E3L.
CETP REVERSES THE RHDL-INDUCED INCREASE IN VLDL

CETP mice
To determine the mechanism underlying the divergent long-term effects of rHDL infusion on plasma was also obtained at 24 h after administration and lipoproteins 44 were fractionated by FPLC (Fig. 8) . In both E3L and E3L.CETP mice, the effect of rHDL on increasing HDL-C levels had disappeared (Fig. 8A, B) . However, whereas rHDL still significantly raised VLDL-C (+60%) (Fig. 8A ) and VLDL-TG (+86%) (Fig. 8C ) in E3L mice, rHDL actually decreased VLDL-C (-25%) in E3L.CETP mice (Fig. 8B ). Since it has been shown that increasing the flux of HDL to the liver can increase the availability of substrate for hepatic VLDL synthesis and subsequently VLDL-TG secretion 23 , we speculated that rHDL may have increased the VLDL production. Therefore, the effect of rHDL on VLDL production was evaluated after injection of Triton WR1339 (tyloxapol)
to block LPL-mediated lipolysis (Fig. 9) . Indeed, at 24 h after administration of rHDL, the VLDL-TG production rate was increased in E3L mice (+36%; P<0.01) (Fig. 9A) . ApoB production was not affected (Fig. 9C) , indicating that rHDL increases lipidation of VLDL particles rather than increasing the VLDL particle secretion rate. Likewise, rHDL tended to increase the VLDL-TG production rate (Fig. 9B ) without affecting the apoB production rate (Fig. 9D ) in E3L.CETP mice. 
CETP REVERSES THE RHDL-INDUCED INCREASE IN VLDL
DiscUssioN
In this study, we investigated the role of CETP in the effects of rHDL on VLDL metabolism by using E3L mice with or without human CETP expression. In both E3L and E3L.CETP mice, rHDL caused a similar transient increase in plasma human apoAI and PL levels and induced a transient increase in the endogenous HDL-C pool. However, rHDL caused an increase in VLDL in E3L mice, at both 1 h and 24 h after injection, which was prevented by CETP expression in E3L.CETP mice.
We observed that rHDL caused a rapid increase in VLDL-TC and VLDL-TG in E3L mice within 1 h after administration. This is in line with previous observations showing that rHDL, composed of human apoAI Milano and PL, also increased the VLDL-TC pool in apoEdeficient mice at 1 h after injection 10 . At an rHDL concentration of 0.625 mg/mL, resulting in an rHDL: TG ratio similar to the in vivo situation, rHDL inhibited LPL activity by as much as 80%. Sucrose and sodium cholate, both present in rHDL, did not inhibit LPL activity in vitro and are thus unlikely to inhibit LPL in vivo. As a consequence of LPL inhibition by rHDL in vivo, the clearance of core remnants is attenuated and plasma VLDL levels are increased. Our finding that normalization of elevated PL levels at 8 h after injection also normalized plasma TG levels in E3L mice is consistent with such a mechanism.
In addition to increasing VLDL at 1 h after injection, rHDL caused a second raise in VLDL-TC and VLDL-TG in E3L mice at 24 h after administration. Since competition of rHDL for VLDL clearance mechanisms can be excluded at this time point, as rHDL has been cleared from the circulation, we hypothesized that rHDL may have caused an increase in hepatic VLDL production. Indeed, we observed that rHDL increased the production rate of VLDL-TG without affecting the production rate of VLDL-apoB. Since each VLDL particle contains a single molecule of apoB, this indicates that rHDL infusion increases the lipidation of hepatic apoB rather than increasing the number of VLDL particles produced. Interestingly, it has previously been observed that increasing the flux of HDL to the liver by hepatic overexpression of SR-BI also increases the VLDL-TG production rate, and that HDL-derived cholesterol can be re-secreted from the liver within VLDL particles 23 . Therefore, we postulate that, in a similar manner, infusion of rHDL causes an increased net flux of lipids to the liver. We did show that rHDL transiently enhanced HDL-C, which may at least partly be attributed by efflux of cholesterol from peripheral tissues. This increased HDL-C may subsequently be taken up by the liver via SR-BI, which could then be re-secreted within VLDL. However, it is even more likely that a high flux of rHDL-associated PL to the liver enhances the amount of hepatic TG available for secretion as VLDL-TG. Indeed, it has been demonstrated that HDL-associated phosphatidylcholine that has been taken up by hepatocytes is converted to TG after phosphatidylcholine-phospholipase C-mediated hydrolysis of phosphatidylcholine resulting in diacylglycerol that is subsequently converted into TG by DGAT2 , diabetes 25 and inflammation 26 . In these clinical studies, no specific adverse VLDL increasing effects have been reported, which is in line with our data that human CETP may protect against rHDL-induced elevation of VLDL.
It is interesting to speculate on the mechanism(s) underlying the protective effect of CETP on the rHDL-induced raise in VLDL. It is well-known that CETP mediates the transfer of CE from HDL particles to LDL and VLDL particles in exchange for TG, and that this reciprocal neutral lipid transfer approaches equilibrium under physiological conditions. However, under conditions of increased VLDL levels as observed at 1 and 24 h after administration of rHDL to E3L mice, the increase in VLDL results in elevated acceptor activity for CETP, which would result in an increased net rate of TG transfer from VLDL particles to both HDL and LDL particles 27 . Both TG-enriched HDL and LDL particles are avidly bound to hepatic lipase (HL) that effectively hydrolyzes TG (as well as PL) to form small dense LDL and HDL, respectively 28 , thereby effectively eliminating TG from plasma.
Based on our data and literature studies, we propose the following mechanism by which CETP has a protective effect on rHDL-induced increase in VLDL. Infusion of rHDL initially decreases VLDL clearance via blocking of LPL-mediated lipolysis and, at a later stage, increases VLDL production via HDL-mediated delivery of lipids to the liver, both of which processes increase plasma VLDL levels. The transient accumulation of VLDL particles leads to an increase of the CETP activity, resulting in an accelerated transfer of TG from VLDL to HDL and LDL, in which TG is hydrolyzed quickly through the action of HL. Since our primary research question was to examine the effect of CETP on the rHDLinduced increase on VLDL metabolism, we used saline as a control for rHDL treatment similarly as applied in clinical trials. It should be noted that such a study set-up does not allow evaluating the individual contributions of apoAI versus lipids. As the cholesterolefflux properties of rHDL could largely depend on the apoAI moiety, it would be interesting to investigate the effect of rHDL as compared to apoAI-free lipid micelles on cholesterol mobilization into plasma as well as VLDL metabolism in future studies. In addition to rHDL infusion therapy, other strategies to raise HDL-C are currently being developed to prevent and treat CVD, alone or combined with LDL-lowering drugs, among which CETP inhibitors. The first CETP inhibitor torcetrapib increased HDL-C levels by approximately 60% 29 , but failed to demonstrate any effect on the primary atherosclerotic burden as assessed by carotid intima-media thickness and coronary intravascular ultrasound imaging 30, 31 and even increased cardiovascular events and mortality, accompanied by off-target effects 32 . However, other CETP inhibitors such as dalcetrapib 33 and anacetrapib 34 have now progressed into phase III clinical trails 48 without showing any off-target toxicity. Additionally, niacin effectively increases HDL by 25-30% 35 and improves carotid intima-media thickness 36 . We recently showed that the HDL-raising effect of niacin is caused by reducing the hepatic CETP expression and plasma CETP protein 37 . Since the HDL-raising effects of CETP inhibitors and niacin thus both depend on reducing CETP activity in plasma, whereas CETP activity now appears crucial to prevent the raise in VLDL as induced by rHDL infusion, combining rHDL with these HDL-raising agents could reveal adverse VLDL effects, and as a consequence counteract the potentially protective effect of rHDL in CVD.
In conclusion, our results show that rHDL infusion induces an increase in VLDL levels, which is prevented by CETP expression. Therefore, we anticipate that studies evaluating the anti-atherosclerotic efficacy of rHDL in mouse models that are naturally deficient for CETP should be interpreted with caution, and that treatment of atherogenic dyslipidemia as a risk factor for CVD by rHDL should not be combined with agents that aggressively reduce CETP activity.
AcKNoWLeDGemeNTs
This work was performed in the framework of the Leiden Center for Cardiovascular
Research LUMC-TNO, and supported by the Netherlands Heart Foundation (NHS grant 2007B81 to P.C.N.R.). P.C.N.R. is an Established Investigator of the Netherlands Heart Foundation (grant 2009T038).
